Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog click here, the HCV drug pipeline click here, and for more information on HCV clinical trials click here
Monday, November 12, 2012
Novartis' Certican succeeds in liver transplant trial
(Reuters) - Swiss pharmaceutical company Novartis said on Monday its Certican, an immune system drug also known under the names Afinitor and Votubia, showed positive outcomes in a two-year phase III study in liver transplantation.
The study, which Novartis said was the largest liver transplant trial to date, confirmed the comparative effectiveness of the treatment and the improved renal function in patients previously noted at the 12-month stage.
The trial evaluated the introduction of Certican (everolimus) with reduced exposure of another immunosuppressive drug tacrolimus administered twice-daily starting one month after liver transplantation versus standard-exposure tacrolimus, Novartis said.